William L. Ashton - 15 Jun 2022 Form 4 Insider Report for Baudax Bio, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 15 Jun 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Jun 2022, 16:13:51 UTC
Prior SEC filing: 20 May 2022
Next SEC filing: 22 Jun 2022
Source filing: View source filing
Reporting owner signature: /s/ Jillian Dilmore, Attorney-in-fact

Key filing fact

William L. Ashton filed Form 4 for Baudax Bio, Inc. on 17 Jun 2022.

Key facts

This page summarizes William L. Ashton's Form 4 filing for Baudax Bio, Inc..
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 17 Jun 2022, 16:13.

Change

Previous filing in this sequence was filed on 20 May 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BXRX transaction

Common Stock

Award

Transaction value: $0
Shares: +39,473
Change %: +1290%
Price: $0.000000
Shares after: 42,534
Date: 15 Jun 2022
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Each Restricted Stock Unit ("RSU") is the economic equivalent of one share of Baudax Bio, Inc. (the "Company") common stock, and may be settled, at the Company's option, in cash, shares of common stock, or a combination thereof. The RSUs vest in full on June 15, 2023, subject to continued service with the Company through the vesting date. Upon vesting, if settled in cash, each RSU will entitle the grantee to a cash-payment equal to the "Fair Market Value" (as defined in the Company's 2019 Equity Incentive Plan) of one share of the Company's common stock on the vesting date.